Richard Beckman's most recent trade in Adverum Biotechnologies Inc was a trade of 225,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 1, 2023.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Adverum Biotechnologies Inc | Richard Beckman | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 225,000 | 225,000 | - | - | Stock Option (Right to Buy) | |
Adverum Biotechnologies Inc | Richard Beckman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 1.07 per share. | 19 Sep 2022 | 4,272 | 39,061 (0%) | 0% | 1.1 | 4,570 | Common Stock |
Adverum Biotechnologies Inc | Richard Beckman | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Sep 2022 | 33,333 | 43,333 (0%) | 0% | 0 | Common Stock | |
Adverum Biotechnologies Inc | Richard Beckman | Chief Medical Officer | Purchase of securities on an exchange or from another person at price $ 0.82 per share. | 17 May 2022 | 10,000 | 10,000 (0%) | 0% | 0.8 | 8,228 | Common Stock |
Adverum Biotechnologies Inc | Richard Beckman | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2022 | 485,000 | 485,000 | - | - | Stock Option (Right to Buy) |